The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric subjects with moderate to severe psoriasis.

Condition	Intervention	Phase
Pediatric plaque psoriasis	Drug: Etanercept	Phase III

Further Study Details: 

Primary Outcomes: Subject incidence of adverse events, including infectious episodes, serious adverse events, and serious infectious episodes
Secondary Outcomes: Injection site reactions; exposure adjusted event rates for adverse events; infections and injection site reactions; physical examination; vital signs; laboratory toxicities; anti-etanercept antibodies; PASI 50; PASI 75; PASI 90; Percent improvement in PASI score; Clear or almost clear status of sPGA; percent improvement in CDLQI; improvement from baseline in joint pain

Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Enrollment on previous Amgen study 20030211

Exclusion Criteria:

• Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept

Study ID Numbers:  20050111
Last Updated:  September 1, 2005
Record first received:  August 31, 2005
ClinicalTrials.gov Identifier:  NCT00141921
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13